Prof. Dr. Kiat Rakrungtham Executive Director of the COVID-19 Vaccine Development Project Vaccine Research Center Faculty of Medicine Chulalongkorn University and Chulalongkorn Hospital, Thai Red Cross Society, revealed the progress of the ChulaCov19 mRNA vaccine development that, in general, it is good news. The early development was found to be safe. It stimulates the immune system to be highly satisfactory. The second phase is the production of vaccines in the country. passed quality assurance And the research team has submitted various documents and information to be considered by the Food and Drug Administration (FDA) for testing in phase 1-2 volunteers. It is expected that they will receive a response soon if the test can meet the goals. Expect to apply for vaccine registration by the end of 2022.
Prof. Dr. Kiat added that Now the epidemic situation in the country is getting better and better. But the research team’s vaccine development did not stop. We would like to see a 1st generation vaccine made by Thai people. Currently, 3 types of vaccines have been developed, namely, Chulalongkorn University’s vaccines, prescription vaccines and the Government Pharmaceutical Organization’s vaccines. And during the application for registration of the first generation vaccine, we developed the second generation vaccine to protect against omikron at the same time. This makes Thailand have its own technology from inventing, designing, testing and producing in the country. Make yourself self-reliant if COVID-19 comes back to spread or a new epidemic emerges. We will be able to develop a vaccine in a faster time. because it can develop the whole chain
